BRCA1 and breast cancer: Development of PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) provides a promising new strategy to target homologous repair‐deficient TNBC breast cancer due to its dysfunctional BRCA1 status (McCann & Hurvitz, 2018; Sulai & Tan, 2018).